Price$15.12+0.15 (+1.00%)
01:30 PM07:45 PM
News · 26 weeks69-22%
2026-01-182026-07-12
Mix4390d
- SEC Filings16(37%)
- Insider12(28%)
- Other8(19%)
- Offering4(9%)
- Earnings2(5%)
- Analyst1(2%)
Latest news
25 items- SECSEC Form S-3 filed by Q32 Bio Inc.S-3 - Q32 Bio Inc. (0001661998) (Filer)
- SECSEC Form 8-K filed by Q32 Bio Inc.8-K - Q32 Bio Inc. (0001661998) (Filer)
- SECSEC Form 424B5 filed by Q32 Bio Inc.424B5 - Q32 Bio Inc. (0001661998) (Filer)
- PRQ32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded WarrantsWALTHAM, Mass., July 14, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the pricing of an underwritten public offering of 6,027,399 shares of its common stock at a public offering price of $18.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 4,931,506 shares of its common stock at a public offering price of $18.2499 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-fu
- SECSEC Form EFFECT filed by Q32 Bio Inc.EFFECT - Q32 Bio Inc. (0001661998) (Filer)
- SECSEC Form 424B5 filed by Q32 Bio Inc.424B5 - Q32 Bio Inc. (0001661998) (Filer)
- PRQ32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsWALTHAM, Mass., July 13, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that it has commenced an underwritten public offering of $200 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Q32 Bio intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissio
- SECSEC Form 8-K filed by Q32 Bio Inc.8-K - Q32 Bio Inc. (0001661998) (Filer)
- SECSEC Form 8-K filed by Q32 Bio Inc.8-K - Q32 Bio Inc. (0001661998) (Filer)
- PRQ32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata-- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline of 35.3% in the prespecified mITT analysis ---- 40.0% of patients achieved SALT-20 response at Week 36 in the mITT analysis and 30.3% of patients achieved SALT-20 response at Week 36 in the ITT analysis of all enrolled patients ---- Generally well-tolerated safety profile, consistent with prior studies, with no new safety signals ---- Bempikibart demonstrated a favorable PK, PD and ADA profile -- -- Data supports further development of bempikibart in alopecia areata; Company intends to advance a registration-directed program in the first half of 2027 ---- Q32
- PRQ32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026-- Conference call to be held Monday, July 13th at 8:00 a.m. E.T. --WALTHAM, Mass., July 10, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced it will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA on Monday, July 13, 2026. Following the announcement, Q32 Bio will host a conference call and webcast at 8:00 a.m. E.T. on Monday, July 13, 2026 to discuss the results.Conference CallQ32 Bio's live conference call an
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Q32 Bio Inc.SCHEDULE 13G/A - Q32 Bio Inc. (0001661998) (Subject)
- INSIDERDirector Manke Isaac exercised 53,521 shares at a strike of $2.80 (SEC Form 4)4 - Q32 Bio Inc. (0001661998) (Issuer)
- SECSEC Form S-3 filed by Q32 Bio Inc.S-3 - Q32 Bio Inc. (0001661998) (Filer)
- INSIDERSEC Form 4 filed by Director Iwicki Mark T4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERSEC Form 4 filed by Director Manke Isaac4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERSEC Form 4 filed by Director Laporte Kathleen4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERSEC Form 4 filed by Director Tzianabos Arthur4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERSEC Form 4 filed by Director Grayzel David S.4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERSEC Form 4 filed by Director Xu Diyong4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERSEC Form 4 filed by Director Thistle Mary4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERSEC Form 4 filed by Director Lundberg Sven Ante4 - Q32 Bio Inc. (0001661998) (Issuer)
- SECSEC Form 8-K filed by Q32 Bio Inc.8-K - Q32 Bio Inc. (0001661998) (Filer)
- INSIDERNew insider Atlas Venture Opportunity Fund Ill, L.P. claimed ownership of 625,000 shares (SEC Form 3)3 - Q32 Bio Inc. (0001661998) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Q32 Bio Inc.SCHEDULE 13G - Q32 Bio Inc. (0001661998) (Subject)
QTTB FAQ
6 questionsWhere does QTTB stock trade?
Q32 Bio Inc. (QTTB) is listed on NASDAQ.What sector and industry is QTTB in?
Q32 Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Q32 Bio Inc. go public?
Q32 Bio Inc. (QTTB) completed its IPO in 2018.What are analysts saying about QTTB?
Q32 Bio Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2026-05-18.What companies are similar to QTTB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare QTTB side-by-side with any of them on Quantisnow.How can I track QTTB on Quantisnow?
Quantisnow aggregates Q32 Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QTTB to receive live email and push alerts on every new disclosure.